AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy

Takao Watanabe 1, Yoshio Tokumoto 2*, Kouji Joko 3, Kojiro Michitaka 4, Norio Horiike 4, Yoshinori Tanaka 5, Fujimasa Tada 6, Yoshiyasu Kisaka 7, Seiji Nakanishi 8, Kazuhiko Yamauchi 9, Hironori Ochi 2, Atsushi Hiraoka 3, Sen Yagi 6, Atsushi Yukimoto 1, Masashi Hirooka 1, Masanori Abe 1 and Yoichi Hiasa 1

Abstract

Background: An unexpected recurrence of hepatocellular carcinoma (HCC) sometimes occurs in patients with hepatitis C virus (HCV) after treatment with direct-acting antivirals (DAAs). However, the characteristics of patients with HCC recurrence may differ depending on time after DAA treatment. We aimed to identify risk factors related to HCC recurrence according to time after DAA treatment.

Methods: Of 1663 patients with HCV treated with a DAA, 199 patients had a previous history of HCC. We defined HCC recurrence within 1 year after DAA treatment as ‘early recurrence’, and recurrence more than 1 year after as ‘late recurrence’. The different risk factors between the early and late phases of HCC recurrence after the end of DAA therapy were investigated.

Results: Ninety-seven patients experienced HCC recurrence during the study period. Incidences of recurrence were 29.8, 41.0, and 53.4% at 1, 2, and 3 years, respectively, after the end of DAA therapy. Multivariate analysis identified post-treatment α-fetoprotein (AFP) as an independent factor contributing to HCC recurrence in the early phase (hazard ratio, 1.056; 95% confidence interval, 1.026–1.087, \( p < 0.001 \)) and post-treatment estimated glomerular filtration rate (eGFR) (hazard ratio, 0.98; 95% confidence interval, 0.96–0.99, \( p = 0.032 \)) as a predictor of HCC recurrence in the late phase.

Conclusion: Patients with higher post-treatment AFP in the early phase and those with lower post-treatment eGFR in the late phase had a high risk of HCC recurrence. The risk factors associated with HCC recurrence after DAA treatment were different between the early and late phases.

Keywords: DAA, Time of recurrence, Renal function, Treatment history, Risk factor, Prediction, Follow-up, HCV, Sex, Male, SVR, Number of treatments, Diabetes mellitus

Introduction

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma (HCC) [1–3]. In addition, HCV infection may promote carcinogenesis. Therefore, the final goal of HCV treatment is eradication of the virus to prevent HCC and/or liver-related death. For decades, interferon (IFN)-based regimens have been the gold standard for treating HCV infection; this therapy is associated with a decreased risk of developing HCC [4–6]. With the recent development of direct-acting antivirals (DAAs), HCV treatment has become much easier because of the short-term and well-tolerated regimens, and a sustained virological response (SVR) is achieved in over 90% of patients.
Recent studies have reported that HCV-infected patients with a prior history of treated HCC and who subsequently achieved SVR with DAA therapies have an increased risk of HCC recurrence [7, 8]. Some studies have shown that the risks of early HCC recurrence after viral eradication are similar between IFN-based and DAA therapies [9, 10], and, furthermore, Waziry et al. performed a meta-analysis and reported that HCC recurrence was not different between IFN-based and DAA therapies [11]. However, even when HCC is completely removed with surgery or percutaneous ablation, it often recurs as intra-hepatic metastasis or multi-centric occurrence. HCC sometimes recurs even after achieving viral eradication with both IFN-based therapy and DAA therapy.

A past study reported that the HCC recurrence rates from the initiation of DAA treatment were 9.6–23.0% at 6 months and 23.1–45.7% at 12 months [12]. Most patients with a history of HCC therapy experienced HCC recurrence relatively early (within about 1 year) after DAA therapy. Moreover, the characteristics of patients with HCC recurrence in the early phase and late phase after completion of IFN-based or DAA treatment may be different [13, 14]. We hypothesized that, in the early phase after the end of anti-HCV treatment, the carcinogenic potential of the liver before beginning anti-HCV therapy may have a strong effect on HCC recurrence after anti-HCV treatment. However, in the late phase, the effects of other unknown risk factors may be present. Nevertheless, no studies have investigated different risk factors depending on time in one cohort.

In this study, we investigated HCC recurrence and risk factors for HCC recurrence after DAA treatment for HCV infection, and we clarified the different risk factors for early phase recurrence and late phase recurrence of HCC after the end of DAA therapy.

Methods

Patients

In this study, we retrospectively reviewed the medical records of 1663 consecutive patients diagnosed with HCV genotype 1 or 2 infection who were treated between 2014 and 2019 with IFN-free DAA regimens at 10 hospitals in the Ehime Kan-en Network (EKEN net). The 10 hospitals were Ehime University Hospital, Matsuyama Red Cross Hospital, Ehime Prefectural Central Hospital, Uwajima City Hospital, Saiseikai Imabari Hospital, Matsuyama Shimin Hospital, Ehime Prefectural Imabari Hospital, Ehime Prefectural Niihama Hospital, Saiseikai Matsuyama Hospital, and National Hospital Organization Ehime Medical Center. Of these patients, 199 patients had a previous history of HCC. Ninety of these 199 patients received 12 weeks of sofosbuvir and ledipasvir therapy, 26 received 12 weeks of sofosbuvir and ribavirin therapy, 53 received 24 weeks of daclatasvir and asunaprevir therapy, 18 received 12 weeks of ombitasvir, paritaprevir, and ritonavir therapy, and 12 received 12 weeks of elbasvir and grazoprevir therapy. We excluded patients who did not have a history of HCC before starting DAA therapy. All patients were confirmed to have no residual HCC prior to the start of DAA therapy by helical dynamic computed tomography (CT) or magnetic resonance imaging (MRI).

We excluded patients receiving warfarin at the start of DAA treatment from the analysis of prothrombin activity (PT %). We defined diabetes mellitus as patients with HbA1c > 6.5% or receiving anti-diabetes drugs or insulin before beginning DAA therapy.

Clinical and laboratory assessments

Prior to DAA treatment, clinical and laboratory tests were performed. The Roche COBAS® TaqMan® HCV Auto assay system (Roche Molecular Diagnostics, Pleasanton, CA), which has a lower limit of detection of 1.2 log_{10} IU/mL, was used to determine HCV RNA levels. To quantitate liver fibrosis, we calculated the FIB-4 index (age (years) × (aspartate aminotransferase (AST) [IU/L]/(platelet count [10^9/L] × (alanine aminotransferase (ALT) [IU/L]}/100/platelet count [10^9/L]) as surrogate markers [15, 16]. These parameters were measured again on completion of DAA treatment and assessed in this study as post-treatment factors.

Follow-up and diagnosis of HCC

Patients treated with DAAAs were monitored every 3 to 6 months, including assessment of biochemical and virological values and blood counts, as well as screening for HCC with ultrasonography, helical dynamic CT, or MRI. For monitoring HCC recurrence, the selection of imaging modalities was at the discretion of the attending physician, with no specific protocol. The presence of typical hypervascular characteristics on angiography, as well as findings on dynamic CT or MRI, was used to diagnose HCC. If typical findings of HCC were not present, fine-needle aspiration biopsy and histological examination were performed to diagnose HCC.

HCC recurrence was defined as ‘early recurrence’ if it was within 1 year after DAA treatment completion and as ‘late recurrence’ if it was more than 1 year after DAA treatment completion.

Statistical analysis

Significant differences were assessed with the χ^2-test, Student’s t-test, or Welch’s t-test, as appropriate. Non-normally distributed parameters were evaluated with Welch’s t-test.

Cox proportional hazard model analyses were used to assess predictors of HCC recurrence following DAA
therapy. Significant predictors that contributed to the recurrence of HCC on univariate analysis were inputted into the multivariate analysis. Hazard ratios (HRs) and 95% confidence intervals (CIs) were also calculated. All \( p \)-values < 0.05 on two-tailed testing were considered significant. The HCC recurrence rate was calculated using the Kaplan-Meier method. Differences in the rates of new HCC were tested with the log-rank test. Data were analyzed statistically using SPSS software ver. 23 (IBM, Armonk, NY, USA).

Results

Patients' characteristics

We enrolled 126 males and 73 females with a median age at treatment initiation of 72 years (Table 1). The platelet count before DAA therapy was 11.9 ± 8.0 \( \times 10^4/\mu \)L, and \( \alpha \)-fetoprotein (AFP) before DAA therapy was 20.8 ± 53.0 ng/mL (means ± standard deviation). Of the 199 patients, 184 (92%) achieved SVR following DAA therapy. At the start of DAA therapy, most patients (80.9%) were Child-Pugh class A. The BCLC stages of enrolled patients [17] at the latest HCC treatment were 81/49/31/35/3 (0/A/B/C/D), respectively.

HCC recurrence rate

The median follow-up time after completion of DAA therapy was 22 months. Ninety-seven patients experienced HCC recurrence during the study period. The incidences of recurrence were 9.0, 16.6, 29.8, 41.0, and 53.4% at 4 and 6 months, and at 1, 2, and 3 years, respectively, after completion of DAA treatment (Fig. 1). Figure 1 also shows the numbers of patients followed up at each time point.

In 97 patients with HCC recurrence, the median time to recurrence was 10 months after the end of DAA treatment. We defined HCC recurrence within 1 year after DAA treatment as ‘early recurrence’, and that more than 1 year after DAA treatment as ‘late recurrence’, as described in the methods section.

Survival rate after DAA therapy

Fourteen patients died during the study period. The incidences of death were 1.0, 2.6, and 6.4% at 1, 2, and 3 years, respectively, after completion of DAA treatment (Fig. S1A). Fig. S1 also shows the numbers of patients followed up at each time point. The survival rate was not significantly different between patients with and without SVR by the log-rank test (\( p = 0.46 \), Fig. S1B). On the other hand, the survival rate was significantly lower in patients with than in those without HCC recurrence (\( p = 0.026 \), Fig. S1C).

| Table 1 | Clinical and virological characteristics of patients with a history of HCC treatments before and after DAA therapy |
|---------|-------------------------------------------------------------------------------------------------|
| Age (years) | 71.7 ± 8.0 |
| Sex (male/female) | 126/73 |
| Body mass index (kg/m²) | 23.2 ± 3.2 |
| White blood cell count (\( \times 10^4/\mu \)L) | 4295 ± 1370 |
| Platelet count (\( \times 10^9/\mu \)L) | 11.9 ± 8.0 |
| ALT (U/L) | 47.1 ± 30.3 |
| AST (U/L) | 52.3 ± 26.7 |
| Total bilirubin (mg/dL) | 0.8 ± 0.4 |
| Albumin (g/dL) | 3.8 ± 0.4 |
| Prothrombin time (%) | 82.9 ± 15.4 |
| AFP (ng/mL) | 20.8 ± 53.0 |
| eGFR (mL/min/1.73 m²) | 67.7 ± 20.3 |
| Total cholesterol (mg/dL) | 151.5 ± 27.9 |
| Diabetes mellitus (no/yes) | 149/49 |
| Alcohol (none/drinking/unknown) | 152/22/25 |
| FIB-4 index | 5.8 ± 3.7 |
| APRI | 1.6 ± 1.5 |
| HCV RNA (log copies/mL) | 5.8 ± 0.7 |
| Post-treatment ALT (U/L) | 22.8 ± 22.4 |
| Post-treatment AST (U/L) | 29.4 ± 16.4 |
| Post-treatment total bilirubin (mg/dL) | 0.8 ± 0.4 |
| Post-treatment albumin (g/dL) | 3.9 ± 0.4 |
| Post-treatment prothrombin time (%) | 83.5 ± 15.8 |
| Post-treatment AFP (ng/mL) | 8.2 ± 10.5 |
| Post-treatment eGFR (mL/min/1.73 m²) | 65.6 ± 19.3 |
| SVR/no SVR | 184/15 |
| Child-Pugh class (A/B/C/unknown) | 161/26/1/1 |
| BCLC stage (0/A/B/C/D) | 81/49/31/35/3 |

Data are expressed as means ± standard deviation

ALT alanine aminotransferase; AST aspartate aminotransferase; AFP \( \alpha \)-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; HCV hepatitis C virus; RNA ribonucleic acid; SVR sustained virological response; BCLC Barcelona Clinic Liver Cancer; RFA radiofrequency ablation; DAA direct-acting antiviral; SOF sofosbuvir; LDV ledipasvir; RBV ribavirin; ASV asunaprevir; DCV daclatasvir; OBV ombitasvir; PTV paritaprevir; r ritonavir; EBR elbasvir; GZR grazoprevir

Predictors of HCC recurrence after the end of DAA treatment in the overall observation period

For the overall period, we assessed parameters present before and after treatment that may have contributed to
HCC recurrence after completion of DAA treatment, as shown in Tables 2 and 3.

Results of univariate analyses are shown in Table 2. Multivariate analysis identified three factors, male sex (hazard ratio (HR) = 1.75; 95% CI 1.09–2.80, \( p = 0.019 \)), no SVR achievement (HR = 2.30; 95% CI 1.17–4.52, \( p = 0.015 \)), and number of treatments for HCC (HR = 1.21; 95% CI 1.07–1.36, \( p = 0.001 \)), as independent factors that contributed to the recurrence of HCC (Table 3).

The recurrence of HCC was examined according to the factors that contributed to the recurrence of HCC after DAA treatment on multivariate analysis (sex, SVR/no SVR, and number of HCC treatments). Cumulative HCC recurrence was significantly higher in male patients than in female patients on the log-rank test (\( p = 0.017 \), Fig. 2a). Similarly, cumulative HCC recurrence was significantly higher in patients without SVR than with SVR (\( p = 0.003 \), Fig. 2b), and recurrence was significantly higher in patients with a history of more than two treatments for HCC than in those with only one treatment for HCC (\( p = 0.001 \), Fig. 2c).

**Recurrence of HCC stratified by a score that combined sex, SVR achievement, and number of HCC treatments**

Based on the results of multivariate analysis, a scoring system that combined sex, SVR achievement, and the number of HCC treatments was developed. Female and male sex were scored as 0 and 1, respectively. Patients with and without SVR were scored as 0 and 1, respectively. Patients with only one treatment and two or more treatments for HCC were scored 0 and 1, respectively. Of the study patients, 39, 88, 66, and 6 had scores of 0, 1, 2, and 3, respectively. The study patients were then grouped based on these scores as follows: 0 points, low-risk group \((n = 39)\); 1 or 2 points, intermediate-risk group \((n = 88)\); and 3 points, high-risk group \((n = 72)\). Figure 2d shows the cumulative incidence curve of HCC recurrence for each group. The 1- and 2-year cumulative incidence rates of HCC recurrence were 12.8 and 22.4% in the low-risk group, 23.2 and 36.8% in the intermediate-risk group, and 46.6 and 55.8% in the high-risk group, respectively. Cumulative HCC recurrence increased significantly with higher scores (\( p < 0.001 \), Fig. 2d).

**Predictors of HCC recurrence after the end of DAA treatment in the early phase**

Pre-treatment factors and post-treatment factors that may have contributed to ‘early recurrence’ after the end of DAA treatment were evaluated. Potential predictors associated with HCC recurrence were the same as those in the analysis of the overall period. Results of univariate analyses are shown in Table 4. Multivariate analysis identified post-treatment AFP (HR = 1.056; 95% CI 1.026–1.087, \( p < 0.001 \)) as an independent factor that
contributed to the recurrence of HCC (Table 5). The log-rank test showed that cumulative HCC recurrence was significantly higher in patients whose post-treatment AFP was $\geq 6.0$ ng/mL than in patients whose post-treatment AFP was $< 6.0$ ng/mL ($p = 0.040$, Fig. 3a). Optimal cut-off values were set in accordance with receiver operating characteristic curve analysis (Fig. S2A). The area under the curve value for the post-treatment AFP was 0.63. The optimal cut-off value for the post-treatment AFP was 6.0 ng/mL, with sensitivity of 57.4% and specificity of 54.0%.

Table 2 Factors associated with the recurrence of HCC after DAA treatment in the overall period

|                     | HCC recurrence | No HCC recurrence | Hazard ratio | 95% CI      | p-value |
|---------------------|----------------|-------------------|--------------|-------------|---------|
| Age (years)         | 71.9 ± 8.1     | 71.5 ± 8.1        | 1.00         | 0.98–1.03   | 0.71    |
| Sex (male/female)   | 70/27          | 56/46             | 1.70         | 1.09–2.66   | 0.013   |
| Body mass index (kg/m$^2$) | 23.1 ± 3.0   | 23.3 ± 3.5        | 0.98         | 0.92–1.05   | 0.79    |
| White blood cell count (/μL) | 4359 ± 1529 | 4235 ± 1207       | 1.00         | 0.99–1.00   | 0.52    |
| Platelet count (×10$^3$/μL) | 123 ± 10.5   | 114 ± 4.6         | 1.00         | 0.98–1.02   | 0.43    |
| ALT (U/L)           | 489 ± 32.5     | 45.4 ± 28.2       | 1.00         | 0.99–1.00   | 0.42    |
| AST (U/L)           | 53.5 ± 25.7    | 51.1 ± 27.6       | 1.00         | 0.99–1.00   | 0.52    |
| Total bilirubin (mg/dL) | 0.8 ± 0.4     | 0.8 ± 0.4         | 0.96         | 0.61–1.52   | 0.89    |
| Albumin (g/dL)      | 3.7 ± 0.4      | 3.8 ± 0.4         | 0.68         | 0.42–1.11   | 0.35    |
| Prothrombin time (%)| 83.3 ± 13.9    | 82.6 ± 16.8       | 1.00         | 0.99–1.01   | 0.78    |
| AFP (ng/mL)         | 22.5 ± 58.8    | 19.1 ± 46.8       | 1.00         | 0.99–1.00   | 0.65    |
| eGFR (mL/min/1.73 m$^2$) | 66.1 ± 19.5   | 69.1 ± 21.0       | 0.99         | 0.98–1.00   | 0.31    |
| Total cholesterol (mg/dL) | 151 ± 29.0    | 151 ± 26.8        | 1.00         | 0.99–1.00   | 0.96    |
| Diabetes mellitus (no/yes) | 68/28         | 81/21             | 1.43         | 0.92–1.00   | 0.18    |
| Alcohol (none/drinking/unknown) | 69/12/21 | 83/10/4           | 0.90         | 0.59–1.38   | 0.18    |
| FIB-4 index         | 5.9 ± 3.8      | 5.7 ± 3.6         | 1.01         | 0.96–1.07   | 0.62    |
| APRI                 | 1.6 ± 1.5      | 1.5 ± 1.5         | 1.04         | 0.92–1.16   | 0.56    |
| Post-treatment white blood cell count (/μL) | 4845 ± 1434 | 4599 ± 1576       | 1.00         | 0.99–1.00   | 0.26    |
| Post-treatment ALT (U/L) | 21.3 ± 10.3   | 24.1 ± 29.4       | 0.99         | 0.97–1.00   | 0.39    |
| Post-treatment AST (U/L) | 28.8 ± 123    | 29.9 ± 19.5       | 0.99         | 0.98–1.00   | 0.64    |
| Post-treatment total bilirubin (mg/dL) | 0.8 ± 0.4     | 0.8 ± 0.3         | 0.98         | 0.60–1.58   | 0.72    |
| Post-treatment albumin (g/dL) | 3.9 ± 0.4     | 3.9 ± 0.3         | 0.76         | 0.48–1.21   | 0.56    |
| Post-treatment prothrombin time (%) | 83.2 ± 14.1   | 83.9 ± 17.2       | 1.00         | 0.98–1.01   | 0.76    |
| Post-treatment AFP (ng/mL) | 9.7 ± 13.0    | 6.4 ± 6.3         | 1.03         | 0.99–1.05   | 0.11    |
| Post-treatment eGFR (mL/min/1.73 m$^2$) | 630 ± 187    | 67.9 ± 19.8       | 0.98         | 0.97–1.00   | 0.10    |
| SVR/no SVR          | 86/11         | 98/4              | 2.55         | 1.35–4.80   | 0.048   |
| Child-Pugh class (A/B/C) | 78/13/1       | 83/13/0           | 1.17         | 0.68–2.02   | 0.58    |
| BCLC stage (0/A/B/C/D) | 37/25/28/16/1 | 44/24/13/19/2     | 1.06         | 0.90–1.25   | 0.75    |
| Number of months from HCC treatment to DAA therapy initiation | 17 ± 25      | 23 ± 26           | 1.00         | 0.99–1.00   | 0.12    |
| Number of curative treatments for HCC | 1.4 ± 1.6 | 0.8 ± 1.3         | 1.23         | 1.09–1.38   | 0.004   |

Table 3 Independent factors associated with the recurrence of HCC after DAA treatment in the overall period according to Cox proportional hazard model analysis

|                     | Hazard ratio | 95% CI      | p-value |
|---------------------|--------------|-------------|---------|
| Male                | 1.75         | 1.09–2.80   | 0.019   |
| No SVR              | 2.30         | 1.17–4.52   | 0.015   |
| Number of curative treatments for HCC | 1.21  | 1.07–1.36   | 0.001   |

Data are expressed as means ± standard deviation

ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; SVR sustained viral response; BCLC Barcelona Clinic Liver Cancer; CI confidence interval
Fig. 2 (See legend on next page.)
Fig. 2 Comparison of cumulative HCC recurrence (%) by sex (A). Cumulative HCC recurrence is significantly higher in males than in females, according to the log-rank test (p = 0.017). Comparison of cumulative HCC recurrence (%) by sustained virological response (SVR) achievement (B). Cumulative HCC recurrence is significantly higher in the 'no SVR' group than in the group with SVR according to the log-rank test (p = 0.003). Comparison of cumulative HCC recurrence (%) between the group with more than two past HCC treatments and the group with only one HCC treatment (C). Cumulative HCC recurrence is significantly higher in the group with more than two past HCC treatments according to the log-rank test (p = 0.001). Cumulative recurrence (%) of HCC according to the score combining sex, SVR achievement, and number of past HCC treatments (D). Study patients are grouped based on these scores: 0 points, low-risk group (n = 39); 1 or 2 points, intermediate-risk group (n = 88); and 3 points, high-risk group (n = 72). Cumulative HCC recurrence increases significantly with higher scores (p < 0.001)

| Table 4 | Factors associated with the recurrence of HCC after DAA treatment in the early phase (within 1 year after DAA treatment completion) |
|---------|------------------------------------------------------------------------------------------------------------------------------------|
| Age (years) | 70.8 ± 8.6 | 71.5 ± 8.1 | 0.99 | 0.96–1.02 | 0.63 |
| Sex (male/female) | 41/17 | 56/46 | 1.71 | 0.97–3.02 | 0.064 |
| Body mass index (kg/m²) | 23.1 ± 2.8 | 23.3 ± 3.5 | 0.99 | 0.91–1.08 | 0.79 |
| White blood cell count (/μL) | 4309 ± 1464 | 4235 ± 1207 | 1.00 | 0.99–1.00 | 0.72 |
| Platelet count (×10⁵/μL) | 10.7 ± 5.1 | 11.4 ± 4.6 | 0.97 | 0.91–1.03 | 0.36 |
| ALT (U/L) | 510 ± 36.2 | 454 ± 28.2 | 1.00 | 0.99–1.01 | 0.28 |
| AST (U/L) | 55.4 ± 27.7 | 51.1 ± 27.6 | 1.00 | 0.99–1.01 | 0.35 |
| Total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4 | 1.14 | 0.64–2.00 | 0.79 |
| Albumin (g/dL) | 3.7 ± 0.4 | 3.8 ± 0.4 | 0.56 | 0.30–1.04 | 0.10 |
| Prothrombin time (%) | 82.1 ± 12.8 | 82.6 ± 16.8 | 0.99 | 0.98–1.01 | 0.82 |
| AFP (ng/mL) | 29.3 ± 74.1 | 19.1 ± 46.8 | 1.00 | 0.99–1.00 | 0.30 |
| eGFR (mL/min/1.73 m²) | 66.8 ± 20.5 | 69.1 ± 21.0 | 0.99 | 0.98–1.00 | 0.50 |
| Total cholesterol (mg/dL) | 150 ± 32.1 | 151 ± 26.8 | 0.99 | 0.98–1.00 | 0.92 |
| Diabetes mellitus (no/yes) | 42/16 | 81/21 | 1.44 | 0.81–2.56 | 0.33 |
| Alcohol (none/drinking/unknown) | 51/4/3 | 69/12/21 | 0.68 | 0.33–1.39 | 0.29 |
| FIB-4 index | 6.6 ± 4.4 | 5.7 ± 3.6 | 1.04 | 0.99–1.10 | 0.33 |
| APRI | 1.9 ± 1.8 | 1.5 ± 1.5 | 1.09 | 0.98–1.21 | 0.33 |
| Post-treatment white blood cell count (/μL) | 4764 ± 1421 | 4599 ± 1576 | 1.00 | 0.99–1.00 | 0.52 |
| Post-treatment ALT (U/L) | 21.2 ± 9.2 | 24.1 ± 29.4 | 0.99 | 0.97–1.01 | 0.47 |
| Post-treatment AST (U/L) | 29.1 ± 9.8 | 29.9 ± 19.5 | 0.99 | 0.97–1.01 | 0.76 |
| Post-treatment total bilirubin (mg/dL) | 0.9 ± 0.4 | 0.8 ± 0.3 | 1.15 | 0.61–2.18 | 0.65 |
| Post-treatment albumin (g/dL) | 3.8 ± 0.5 | 3.9 ± 0.3 | 0.63 | 0.34–1.16 | 0.29 |
| Post-treatment prothrombin time (%) | 82.5 ± 14.3 | 83.9 ± 17.2 | 0.99 | 0.98–1.01 | 0.62 |
| Post-treatment AFP (ng/mL) | 119 ± 15.5 | 64 ± 6.3 | 1.04 | 1.02–1.06 | 0.028 |
| Post-treatment eGFR (mL/min/1.73 m²) | 635 ± 18.2 | 679 ± 19.8 | 0.99 | 0.97–1.00 | 0.19 |
| SVR/no SVR | 48/10 | 98/4 | 2.85 | 1.43–5.64 | 0.007 |
| Child-Pugh class (A/B/C) | 46/9/1 | 83/13/0 | 1.46 | 0.77–2.75 | 0.37 |
| BCLC stage (0/A/B/C/D) | 18/16/14/10/0 | 44/24/13/19/2 | 1.10 | 0.89–1.37 | 0.22 |
| Number of months from HCC treatment to DAA therapy initiation | 12 ± 14 | 23 ± 26 | 0.99 | 0.99–0.99 | 0.001 |
| Number of curative treatments for HCC | 1.7 ± 1.7 | 0.8 ± 1.3 | 1.25 | 1.10–1.41 | 0.001 |
Table 5 Independent factors associated with the recurrence of HCC after DAA treatment in the early phase (within 1 year after DAA treatment completion) according to Cox proportional hazard model analysis

| Hazard ratio | 95% CI          | p-value |
|--------------|-----------------|---------|
| Post-treatment AFP (ng/mL) | 1.056 | 1.026–1.087 | < 0.001 |

Data are expressed as means ± standard deviation

ALT: alanine aminotransferase; AST: aspartate aminotransferase; AFP: α-fetoprotein; eGFR: estimated glomerular filtration rate; FIB-4 index; APRI: AST to platelet ratio index; SVR: sustained viral response; BCLC: Barcelona Clinic Liver Cancer; CI: confidence interval

Predictors of HCC recurrence after the end of DAA treatment in the late phase

Pre-treatment factors and post-treatment factors that may have contributed to ‘late recurrence’ after the end of DAA treatment were evaluated. Potential predictors associated with HCC recurrence were the same as those in the analysis of the overall period. Results of univariate analyses are shown in Table 6. Multivariate analysis identified post-treatment post-treatment estimated glomerular filtration rate (eGFR) (HR = 0.98; 95% CI 0.96–0.99, p = 0.032) as an independent factor that contributed to the recurrence of HCC. The log-rank test showed that cumulative HCC recurrence was significantly higher in patients whose post-treatment eGFR was ≤ 70 mL/min/1.73 m^2 than in patients whose post-treatment eGFR was > 70 mL/min/1.73 m^2 (p = 0.008, Fig. 3b). Optimal cut-off values were set in accordance with receiver operating characteristic curve analysis (Fig. S2B). The area under the curve value for the post-treatment eGFR was 0.64. The optimal cut-off value for the post-treatment eGFR was 70 mL/min/1.73 m^2, with a sensitivity of 57.3% and specificity of 72.2%. To clarify the features of patients whose post-treatment eGFR was ≤ 70 mL/min/1.73 m^2 at the end of DAA treatment were evaluated. Age (p = 0.017) and the number of curative treatments for HCC (p = 0.021) were associated with eGFR ≤ 70 mL/min/1.73 m^2 at the end of DAA treatment (Table S1). Patients with eGFR ≤ 70 mL/min/1.73 m^2 at the end of DAA treatment were often those with multiple past HCC treatments.

Even among patients with post-treatment eGFR > 70 mL/min/1.73 m^2, 10 patients had late recurrence of HCC after DAA treatment. We evaluated the factors associated with no recurrence of HCC in the late phase (more than 1 year after DAA treatment completion) in patients with eGFR > 70 mL/min/1.73 m^2 at the end of DAA treatment. The absence of diabetes mellitus was identified as a factor that contributed to no recurrence in the late phase in patients with post-treatment eGFR > 70 mL/min/1.73 m^2 (p = 0.038, Table S2). On the log-rank test, the cumulative incidence of late HCC recurrence was significantly higher in patients with diabetes mellitus than in those without diabetes mellitus in patients with post-treatment eGFR > 70 mL/min/1.73 m^2 (p = 0.019, Fig. 3c).

Discussion

Previous studies have examined parameters that may predict HCC recurrence after DAA therapy. The cumulative incidence of HCC recurrence is lower in patients who achieve SVR compared to those who do not [9, 18, 19]. Guarino et al. reported a significant inverse relationship between SVR and risk of HCC recurrence [12]. Thus, achieving SVR is an important parameter to predict future HCC recurrence.

The HR was 2.22 for HCC recurrence after DAA therapy in patients with previous HCC recurrence compared to those without previous HCC recurrence (only one treatment for HCC [20]). Thus, a prior history of HCC recurrence before DAA therapy also affected HCC recurrence after DAA [18, 20, 21].

In the present study, independent factors associated with the recurrence of HCC after DAA treatment in the overall period according to Cox proportional hazard model analyses were male sex, no SVR, and the number of curative treatments for HCC. Although SVR achievement and the number of curative treatments were similar to the previous reports described above, male sex had not been reported. HCC is a male-dominant cancer [22], and irrespective of the etiology, rates of HCC are two to four times higher in men than in women. Several studies have reported that males are at high risk of developing HCC after IFN-based therapy [23, 24]. In the present results, sex difference also affected HCC recurrence after IFN-free DAA regimens [25]. As in some previous reports, in the present study, absence of SVR was strongly associated with recurrence after DAA therapy. Thus, an analysis was conducted excluding patients who did not achieve SVR. However, both in the early phase and the late phase, the risk factors for recurrence of HCC after DAA therapy were the same as those including patients without SVR (data not shown).

We identified one independent factor, post-treatment AFP, that was associated with early recurrence of HCC. Serum AFP levels are often increased in patients with HCC, and thus, the AFP level is commonly used as a surrogate marker for HCC [26]. In patients with IFN-based therapy, post-treatment AFP levels are significantly associated with HCC occurrence, and higher AFP levels, even after these treatments, are associated with a higher risk of developing HCC [27, 28]. In patients undergoing DAA treatment, we recently reported that a higher FIB-4 index and higher post-treatment AFP are independent risk factors for de novo HCC development (without previous HCC treatment patients) [29]. In addition, post-treatment AFP is an independent factor...
associated with early recurrence of HCC within 6 months after antiviral therapy [13]. In our analysis of the overall period, the AFP level was not identified as an independent factor, and thus, a higher level of post-treatment AFP may be a specific risk factor associated with HCC recurrence in the early phase.

On the other hand, in late phase recurrence, post-treatment eGFR \( \leq 70 \) mL/min/1.73 m\(^2\) was the only independent risk factor identified in this study. This factor has not been reported in past studies, but post-treatment eGFR \( \leq 70 \) mL/min/1.73 m\(^2\) was associated with the number of past HCC treatments (Supplemental Table 1), which was a risk factor for HCC recurrence after DAA treatment. Some patients with a post-treatment eGFR > 70 mL/min/1.73 m\(^2\) experienced HCC recurrence in the late phase after DAA treatment. In patients with post-treatment eGFR > 70 mL/min/1.73 m\(^2\), those without diabetes mellitus had a lower risk of HCC recurrence than those with diabetes mellitus (Supplemental Table 2). In IFN therapy, abnormalities in glucose metabolism are significantly associated with HCC development [24]. Recently, Degasperi et al. reported that diabetes is independently associated with HCC recurrence in patients who received DAA treatment [30].

BCLC stage was determined by tumor status, liver function, and performance status. This study included 38 patients with BCLC stage C or D who were expected to have a poor prognosis and might not be candidates for curative treatments such as radiofrequency ablation or surgical resection. However, since all of these patients had no vascular invasion or extrahepatic metastases, and their performance status was \( \geq 1 \), they were considered eligible for curative treatment by their treating physicians. Therefore, BCLC stage was not identified as a significant factor for recurrence in this study.

The HCC recurrence rate may depend on the period after DAA treatment [12], and most patients with previous HCC treatment had experienced HCC...
recurrence in a relatively early time. Patients with early recurrence may have already had invisible HCC before DAA treatment, and, thus, factors associated with HCC were predictive. On the other hand, after a period of time, these factors may not have an effect on late recurrence, because the effect of factors associated with HCC before treatment is attenuated. Therefore, the characteristics of patients with HCC recurrence in the early phase may be different from those with recurrence in the late phase after completion of DAA treatment. However, before our report, few studies had clearly shown differences in risk factors according to the period after the end of DAA treatment.

Table 6  Factors associated with the recurrence of HCC after DAA treatment in the late phase (more than 1 year after DAA treatment completion)

|                                | HCC recurrence | No HCC recurrence | Hazard ratio | 95% CI       | p-value |
|--------------------------------|----------------|-------------------|--------------|--------------|---------|
| Age (years)                    | 73.5 ± 7.0     | 70.6 ± 8.1        | 1.04         | 0.99–1.08    | 0.062   |
| Sex (male/female)              | 29/10          | 48/39             | 2.15         | 1.04–4.42    | 0.049   |
| Body mass index (kg/m²)        | 23.1 ± 3.2     | 23.3 ± 3.6        | 0.97         | 0.88–1.07    | 0.79    |
| White blood cell count (µL)    | 4435 ± 1641    | 4311 ± 1250       | 1.00         | 0.99–1.00    | 0.64    |
| Platelet count (x10³/µL)       | 148 ± 15.2     | 114 ± 4.6         | 1.01         | 0.99–1.03    | 0.064   |
| ALT (U/L)                      | 45.6 ± 26.1    | 46.7 ± 29.1       | 0.99         | 0.98–1.00    | 0.84    |
| AST (U/L)                      | 50.7 ± 22.3    | 52.2 ± 28.5       | 0.99         | 0.98–1.00    | 0.76    |
| Total bilirubin (mg/dL)        | 0.8 ± 0.4      | 0.8 ± 0.4         | 0.75         | 0.35–1.60    | 0.80    |
| Albumin (g/dL)                 | 3.8 ± 0.4      | 3.8 ± 0.4         | 1.05         | 0.48–2.28    | 0.79    |
| Prothrombin time (%)           | 85.1 ± 15.5    | 81.6 ± 16.6       | 1.01         | 0.99–1.03    | 0.28    |
| AFP (ng/mL)                    | 12.2 ± 14.8    | 17.6 ± 40.9       | 0.99         | 0.97–1.01    | 0.43    |
| eGFR (mL/min/1.73 m²)          | 65.1 ± 183     | 71.6 ± 19.4       | 0.98         | 1.00–1.02    | 0.020   |
| Total cholesterol (mg/dL)      | 152 ± 23       | 151 ± 26          | 1.00         | 0.99–1.02    | 0.85    |
| Diabetes mellitus (no/yes)     | 26/12          | 70/17             | 1.77         | 0.89–3.51    | 0.16    |
| Alcohol (none/drinking/unknown)| 32/6/1         | 62/12/3           | 1.29         | 0.74–2.25    | 0.23    |
| FIB-4 index                    | 4.9 ± 2.5      | 5.7 ± 3.7         | 0.89         | 0.78–1.01    | 0.24    |
| APRI                           | 1.2 ± 0.7      | 1.5 ± 1.6         | 0.65         | 0.41–1.02    | 0.24    |
| Post-treatment white blood cell count (µL) | 4964 ± 1465 | 4710 ± 1606       | 1.00         | 0.99–1.00    | 0.41    |
| Post-treatment ALT (U/L)       | 215 ± 11.9     | 250 ± 31.6        | 0.99         | 0.97–1.01    | 0.52    |
| Post-treatment AST (U/L)       | 28.4 ± 15.5    | 30.5 ± 20.6       | 0.98         | 0.96–1.01    | 0.58    |
| Post-treatment total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4         | 0.78         | 0.35–1.73    | 0.98    |
| Post-treatment albumin (g/dL)  | 3.9 ± 0.4      | 3.9 ± 0.3         | 1.03         | 0.48–2.21    | 0.61    |
| Post-treatment prothrombin time (%) | 84.3 ± 13.9 | 82.8 ± 17.3       | 1.00         | 0.98–1.02    | 0.67    |
| Post-treatment AFP (ng/mL)     | 6.0 ± 5.3      | 6.6 ± 6.6         | 0.97         | 0.90–1.05    | 0.69    |
| Post-treatment eGFR (mL/min/1.73 m²) | 62.7 ± 196  | 70.6 ± 17.0       | 0.98         | 0.96–0.99    | 0.013   |
| SVR/no SVR                     | 38/1           | 84/3              | 0.78         | 0.10–5.73    | 1.00    |
| Child-Pugh class (A/B/C)       | 32/4/0         | 71/12/0           | 0.68         | 0.24–1.93    | 0.77    |
| BCLC stage (0/A/B/C/D)         | 19/9/4/6/1     | 39/20/12/15/1     | 0.97         | 0.74–1.28    | 0.94    |
| Number of months from HCC treatment to DAA therapy initiation | 25 ± 34 | 21 ± 23 | 1.00 | 0.99–1.00 | 0.51 |
| Number of curative treatments for HCC | 1.0 ± 1.2 | 0.8 ± 1.4 | 1.13 | 0.89–1.43 | 0.44 |

Table 7  Independent factors associated with the recurrence of HCC after DAA treatment in the late phase (more than 1 year after DAA treatment completion) according to Cox proportional hazard model analysis

|                                | Hazard ratio | 95% CI       | p-value |
|--------------------------------|--------------|--------------|---------|
| Post-treatment eGFR (mL/min/1.73 m²) | 0.98         | 0.96–0.99    | 0.032   |

Data are expressed as means ± standard deviation
ALT alanine aminotransferase; AST aspartate aminotransferase; AFP α-fetoprotein; eGFR estimated glomerular filtration rate; FIB-4 fibrosis-4; APRI AST to platelet ratio index; SVR sustained viral response; BCLC Barcelona Clinic Liver Cancer; CI confidence interval
Conclusions
In conclusion, risk factors associated with HCC recurrence after DAA therapies are different in the early (within 1 year after DAA treatment) and late phases. Patients with a higher level of post-treatment AFP within 1 year, and after 1 year, those with a history of more than two treatments for HCC or those with diabetes mellitus, which are related to post-treatment eGFR, require careful attention regarding the possibility of HCC recurrence.

Acknowledgments
Not applicable.

Authors’ contributions
Study design: T.W., M.A., Y.T.1. Data acquisition: T.W., K.J., K.M., N.H., Y.T.2, F.T., Y.K., S.N., K.H., A.H., S.Y. Quality control of data and algorithms: T.W., Y.T.1. M.H. Data analysis and interpretation: T.W., Y.T.1, M.H. Statistical analysis: T.W., A.Y., Y.T.1. Manuscript preparation: T.W., Y.T.1. Manuscript editing: T.W., Y.H. Manuscript review: M.A., Y.H. The author(s) read and approved the final manuscript.

Funding
This work was partially funded by JSPS KAKENHI (No. JP20K08388) to TW, and JSPS KAKENHI (No. JP18K08007) to YH. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-021-08401-7.

Additional file 1: Supplementary Figure 1. The survival rate (%) after DAA therapy by Kaplan-Meier method (A). Comparison of survival rate (%) by sustained virological response (SVR) achievement (B). The survival rate is not significantly different between patients with and without SVR according to the log-rank test. Comparison of survival rate (%) by HCC recurrence after DAA therapy (C). The survival rate is significantly lower in the group with DAA recurrence than in the group without HCC recurrence after DAA therapy according to the log-rank test (p = 0.026).

Additional file 2: Supplementary Figure 2. Receiver operating characteristic (ROC) curves for the post-treatment eGFR to predict HCC recurrence in early phase (within 1 year after DAA treatment). The area under the curve (AUC) value for the post-treatment eGFR is 0.63 (A). Receiver operating characteristic (ROC) curves for the post-treatment eGFR to predict HCC recurrence in late phase (more than 1 year after DAA treatment). The area under the curve (AUC) value for the post-treatment eGFR is 0.64 (B).

Additional file 3. Supplementary Table 1. Factors associated with eGFR ≤ 70 mL/min/1.73 m² at the end of DAA treatment.

Additional file 4. Supplementary Table 2. Factors associated with no HCC recurrence in the late phase (more than 1 year after DAA treatment completion) among patients with eGFR > 70 mL/min/1.73 m² at the end of DAA treatment.

Declarations
Ethics approval and consent to participate
This study was approved by The Ethics Committee of Ehime University Hospital (approval ID 1411010) and was conducted in compliance with the ethical guidelines of the Declaration of Helsinki amended in 2008. Written informed consent was obtained from all patients for being included in the study.

Consent for publication
Not applicable.

Competing interests
All authors declare that they have no conflict of interests.

Author details
1. Department of Gastroenterology and Metabolology, Ehime University Graduate School of Medicine, Shihokuwaka, Toon, Ehime 791-0295, Japan. 2. Center for Liver-Biliary-Pancreatic Diseases, Matsuyama Red Cross Hospital, 1 Bunkyocho, Matsuyama, Ehime 790-8524, Japan. 3. Department of Gastroenterology, Ehime Prefectural Central Hospital, 83 Kasugamachi, Matsuyama, Ehime 790-0024, Japan. 4. Department of Gastroenterology, Saiseikai Imabari Hospital, 7-1-6 Kitamara, Imabari, Ehime 799-1502, Japan. 5. Department of Gastroenterology, Matsuyama Shimin Hospital, 2-6-5 Otemachi, Matsuyama, Ehime 790-0007, Japan. 6. Department of Internal Medicine, Saiseikai Matsuyama Hospital, 880-2 Yamanishicho, Matsuyama, Ehime 791-8026, Japan. 7. Department of Gastroenterology, Uwajima City Hospital, 1-1 Gotenmachi, Uwajima, Ehime 798-8510, Japan. 8. Department of Gastroenterology, Ehime Prefectural Imabari Hospital, 4-5-5 Ishicho, Imabari, Ehime 794-0006, Japan. 9. Department of Gastroenterology, National Hospital Organization Ehime Medical Center, 366 Yokogawara, Toon, Ehime 791-0203, Japan.

Received: 22 October 2020 Accepted: 24 May 2021

Published online: 14 June 2021

References
1. Manns MP, von Hahn T. Novel therapies for hepatitis C—one pill fits all? Nat Rev Drug Discov. 2013;12(8):595–610. https://doi.org/10.1038/nrd4050.
2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1393–414.
3. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264–73. https://doi.org/10.1053/j.gastro.2011.12.061.
4. Kasahara A, Hayashi N, Mochizuki T, Takayangi M, Yoshikawa K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon therapy in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1996;27:1194–402.
5. Ikeka K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kubayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29(4):1124–30. https://doi.org/10.1002/hep.10290439.
6. Hiramatsu N, Oze T, Takehara T. Suppression of hepatocellular carcinoma development in hepatitis C patients given interferon-based anti-viral therapy. Hepatol Res. 2015;5:152–61.
7. Reig M, Marín Z, Perelló C, Iñarraírategui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–26. https://doi.org/10.1016/j.jhep.2016.04.008.
8. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):277–93. https://doi.org/10.1016/j.jhep.2016.05.015.
9. Nagata H, Nakagawa M, Ashihara Y, Sato A, Asano Y, Tsunoda T, et al. Effect of interferon-based and–free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol. 2017;67(3):933–9. https://doi.org/10.1016/j.jhep.2017.05.028.
10. Nagaki Y, Imamura M, Nishida Y, Daio K, Terakoa Y, Honda F, et al. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma.
comparison with interferon-based therapy. J Med Virol. 2019;91(4):550–8. https://doi.org/10.1002/jmv.25352.

11. Wazny R, Hajarizadeh B, Ghebely J, Amini J, Law M, Danta M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204–12. https://doi.org/10.1016/j.jhep.2017.07.025.

12. Guarino M, Viganò L, Pondiani FR, Giannini EG, Lai Q, Morisco F, et al. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: literature review and risk analysis. Dig Liver Dis. 2018;50(11):1105–14. https://doi.org/10.1016/j.dld.2018.08.001.

13. Mashita T, Joko K, Kuroasaki M, Ochi H, Osaki Y, Kojima Y, et al. Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One. 2018;13:e0194704.

14. Shinkawa H, Hasegawa K, Arita J, Akamatsu N, Kaneko J, Sakamoto Y, et al. Impact of sustained Virological response to interferon therapy on recurrence of hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2017;24(1):3190–202. https://doi.org/10.1245/s10434-017-6008-y.

15. Vallée-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. Fib4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–6. https://doi.org/10.1002/hep.21669.

16. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26. https://doi.org/10.1053/jhep.2003.50346.

17. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.

18. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62(10):2932–42. https://doi.org/10.1007/s10620-017-4739-z.

19. Petta S, Cabibbo G, Barbara M, Attardo S,ucci L, Farinati F, et al. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther. 2017;45(1):160–8. https://doi.org/10.1111/apt.13821.

20. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, Madonia S, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017;46(7):688–95. https://doi.org/10.1111/apt.14256.

21. Kanda T, Lau GK, Wei L, Moriya M, Yu ML, Chuang WL, et al. APASL HCV guidelines of virus-eradicated patients by DAAs on how to monitor HCC occurrence and HBV reactivation. Hepatol Int. 2019;13(6):649–61. https://doi.org/10.1111/hepi.13951.

22. Akita T, Ohisa M, Kinuwa Y, Fujimoto M, Miyazawa Y, Tanaka J. Validation and limitation of age-period-cohort model in simulating mortality due to hepatocellular carcinoma from 1940 to 2010 in Japan. Hepatol Res. 2014;44(7):713–9. https://doi.org/10.1111/hepr.12177.

23. Makijarvi A, Itok Y, Kasahara A, Inami Y, Kawata S, Yoshikawa K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;1:1616–22.

24. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):963–6. https://doi.org/10.1002/hep.26442.

25. Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horikae N, Tanaka Y, et al. Post-treatment levels of α-fetoprotein predict incidence of hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol. 2014;12(7):1186–95. https://doi.org/10.1016/j.cgh.2013.11.033.

26. Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horikae N, Tanaka Y, et al. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49(2):136–46. https://doi.org/10.1111/hepr.13278.

27. Degasperi E, D’Ambrosio R, Iavarone M, Sangiovanni A, Aghemo A, Soffredini R, et al. Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection. Clin Gastroenterol Hepatol. 2019;17(6):1183–91. https://doi.org/10.1016/j.cgh.2018.10.038.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.